logo

Cormedix Inc. (CRMD)



Trade CRMD now with
  Date
  Headline
8/14/2014 4:56:43 PM FDA Accepts CorMedix Pivotal Phase 3 Study Protocol
3/10/2014 4:25:00 PM CorMedix Closes Direct Offering Stock And Warrant For Proceeds Of $7.4 Mln
3/4/2014 9:53:06 PM CorMedix Enters Deal With Investors For Registered Direct Offering Of 2.96 Mln Units At $2.50 For Proceeds Of $7.4 Mln
1/10/2014 8:33:12 AM CorMedix Awarded European Patent For Neutrolin
1/8/2014 9:17:42 AM CorMedix To Raise $2 Mln In Follow On Offering
12/23/2013 9:52:28 AM CorMedix Receives Minutes From Neutrolin Pre-IND Meeting With FDA
9/5/2013 7:02:34 AM CorMedix Reports Receipt Of European Patent Office Decision To Allow Prosl Patent To Proceed In European Union
8/14/2013 6:51:43 PM CorMedix Q2 Loss Per Share $0.15 Vs Loss $0.05 Last Year
7/5/2013 11:06:09 AM CorMedix Gets CE Mark For Neutrolin Catheter Lock Solution
5/31/2013 4:18:05 PM CorMedix Granted Extension Of NYSE MKT Listing
4/22/2013 8:18:11 AM Glu Mobile Appoints Chris Akhavan As President Of Publishing
4/11/2013 4:33:11 PM CorMedix Notified Of NYSE MKT Listing Deficiency
3/27/2013 5:13:21 PM CorMedix Posts FY12 Loss Per Share Of $0.30 Vs. Loss $0.59 Year Ago